FDA Approves Nexavar for Thyroid Cancer

Bayer/Onyx drug gains expanded indication

The FDA has expanded the approved use of the cancer drug Nexavar to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.

Nexavar is made by Bayer AG and Onyx Pharmaceuticals and is also approved to treat advanced kidney cancer and liver cancer. Onyx was acquired by Amgen earlier this year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters